Recombinant Human Transmembrane protein 246 (TMEM246)

What is TMEM246 and what is its primary biological function?

TMEM246, also known as post-GPI attachment to proteins factor 4 (PGAP4), is a transmembrane protein that functions as a GPI-specific GalNAc transferase. It catalyzes a critical step in the modification of glycosylphosphatidylinositol (GPI) anchors . Specifically, TMEM246 is responsible for adding an N-acetylgalactosamine (GalNAc) side chain to the GPI-anchor, which serves as a foundation for further modifications .

The protein is encoded by the TMEM246 gene, which produces a multi-pass transmembrane protein that localizes primarily to the endoplasmic reticulum (ER) . This localization is consistent with its role in the early stages of GPI-anchor biosynthesis and modification, which occurs predominantly in the ER before proteins are transported to their final destinations.

How is TMEM246 involved in GPI-anchor biosynthesis and what are the consequences of its dysfunction?

TMEM246/PGAP4 specifically catalyzes the transfer of GalNAc to GPI anchors, representing a crucial step in the maturation of GPI-anchored proteins . This post-translational modification is essential for the proper functioning of many cell surface proteins.

When TMEM246 function is disrupted:

• The GalNAc side chain of the GPI-anchor is absent

• This absence affects the normal processing and localization of GPI-anchored proteins

• Downstream galactosylation and sialylation of the GPI anchor may be impaired

• Cellular processes dependent on properly modified GPI-anchored proteins are disrupted

Research using PGAP4-KO (TMEM246 knockout) mice has demonstrated that loss of the GalNAc side chain results in observable phenotypic consequences, indicating the physiological importance of this modification .

What experimental models are available for studying TMEM246 function?

Several experimental models have been developed to study TMEM246:

Knockout Mouse Models:

• PGAP4-KO mice have been generated using CRISPR-Cas9 gene editing technology

• These models feature in-frame insertion of EGFP sequences into the Pgap4 allele

• The knockout construct allows visualization of TMEM246-expressing cells via EGFP fluorescence

• Specific phenotypes in these models can be assessed using immunofluorescence and Western blotting

Cell Culture Systems:

• PIGS-KO HEK293 cells with additional knockout of TMEM246 using CRISPR-Cas9

• These systems allow for assessment of GPI-anchor modifications in controlled environments

Recombinant Expression Systems:

• cDNA ORF clones of TMEM246 are available for expression in mammalian cell systems

• Standard vectors like pcDNA3.1+/C-(K)DYK can be used for expression studies

How can TMEM246 expression be detected in experimental settings?

Detection of TMEM246 expression and function can be accomplished through several methodologies:

Protein Detection:

• Western blotting using specific antibodies against TMEM246

• Immunofluorescence microscopy to visualize cellular localization

• In PGAP4-KO mouse models with EGFP insertion, TMEM246-expressing cells can be directly visualized through EGFP fluorescence

Functional Assays:

• T5 mAb staining, which recognizes free GPI when it has the GalNAc side chain

• This approach allows for assessment of TMEM246 enzymatic activity by detecting its product

• Comparative staining between wild-type and knockout samples provides functional evidence

Transcriptomic Analysis:

• RT-PCR or RNA-seq to detect TMEM246 mRNA expression

• Microarray analysis to identify changes in gene expression profiles related to TMEM246 function

What is the relationship between TMEM246 and disease states, particularly in cancer?

TMEM246 and its antisense transcript TMEM246-AS1 have been implicated in several disease states:

Renal Cell Carcinoma (RCC):

• TMEM246-AS1 exhibits protective values in RCC prognostic analyses

• Lower expression of TMEM246-AS1 is associated with poor prognosis in kidney cancer

• Expression is correlated with clinicopathological characteristics including T, M, and stage

Acute Erythroid Leukemia (AEL):

• TMEM246 shows differential expression in certain genomic subgroups of AEL

• It is part of gene expression signatures that can be used for classification and prognostication

• May be overexpressed in specific subtypes, potentially serving as a biomarker

The correlation between TMEM246-AS1 expression and clinical parameters in RCC is summarized in the table below:

What methodological approaches can be used to study TMEM246 interactions with other proteins in the GPI biosynthetic pathway?

Studying protein-protein interactions involving TMEM246 requires sophisticated methodological approaches:

Co-immunoprecipitation (Co-IP):

• Use antibodies against TMEM246 to pull down the protein complex

• Analyze binding partners through Western blotting or mass spectrometry

• This approach has revealed that TMEM246 complexes with other proteins involved in GPI biosynthesis

Proximity Labeling Techniques:

• BioID or APEX2-based proximity labeling to identify proteins in close proximity to TMEM246

• These methods involve fusion of a biotin ligase to TMEM246 and subsequent purification of biotinylated proteins

Crosslinking Mass Spectrometry:

• Chemical crosslinking followed by mass spectrometry can identify direct binding partners

• This approach was used in studying the interaction between GPI biosynthesis and ER quality control systems

Fluorescence Resonance Energy Transfer (FRET):

• Tag TMEM246 and potential binding partners with appropriate fluorophores

• Measure energy transfer as an indicator of physical proximity

Research has identified cross-talks between GPI biosynthesis (involving TMEM246) and:

• Glycosphingolipid biosynthesis pathways

• ER quality control systems, including ERAD components

How can CRISPR-Cas9 genome editing be optimized for studying TMEM246 function?

CRISPR-Cas9 has proven invaluable for studying TMEM246 function through the generation of knockout models. Optimization strategies include:

Guide RNA Selection:

• Design multiple sgRNAs targeting different exons of TMEM246

• Prioritize guides with high on-target and low off-target scores

• For functional studies, target catalytic domains crucial for GalNAc transferase activity

Knockout Strategy Design:

• In-frame insertion of reporter genes (e.g., EGFP) to track expression

• This approach allows visualization of endogenously TMEM246-expressing cells and tissues

• Example: The PGAP4-KO mouse model was created by inserting EGFP into the Pgap4 allele

Validation Methods:

• PCR-based genotyping to confirm desired genetic modifications

• Western blotting to verify protein absence

• Functional assays using T5 mAb to confirm loss of GalNAc modification

• Phenotypic rescue experiments by reintroducing wild-type TMEM246

Cellular Phenotype Assessment:

• Analyze changes in GPI-anchored protein localization and function

• Examine alterations in cellular processes like signaling pathways or membrane trafficking

• Investigate compensatory mechanisms activated in response to TMEM246 loss

What approaches can be used to produce and purify recombinant TMEM246 for structural and functional studies?

Producing recombinant transmembrane proteins like TMEM246 presents significant technical challenges. Effective approaches include:

Expression Systems:

• Mammalian expression systems (e.g., CHO cells) are preferred for proper folding and post-translational modifications

• Use of DHFR-deficient CHO cells (DXB11 or DG44) with methotrexate-based amplification system can enhance expression

• Transfection and selection typically involves co-transfection with the DHFR gene and selection in media lacking glycine, hypoxanthine, and thymidine

Vector Design:

• ORF sequences can be delivered in standard vectors like pcDNA3.1+/C-(K)DYK

• Addition of epitope tags (His, FLAG) facilitates purification

• Codon optimization improves expression efficiency in the chosen host system

Purification Strategy:

• Detergent solubilization (e.g., DDM, LMNG) to extract membrane proteins

• Affinity chromatography using tags

• Size exclusion chromatography for final purification

Reconstitution Methods:

• Reconstitution into proteoliposomes or nanodiscs for functional studies

• These approaches maintain the native membrane environment necessary for activity

The purification process must be carefully optimized to maintain the structural integrity and enzymatic activity of TMEM246, as improper handling can lead to protein aggregation or denaturation.

How do alterations in TMEM246 expression impact related cellular pathways and global gene expression?

Alterations in TMEM246 expression have far-reaching effects on cellular pathways:

GPI-Anchor Modification Pathway:

• Loss of TMEM246 prevents GalNAc addition to GPI anchors

• This affects subsequent modifications like galactosylation and sialylation

• Altered GPI structures impact the localization and function of GPI-anchored proteins

ER Quality Control and ERAD Pathways:

• Research has identified cross-talk between GPI biosynthesis and ERAD components

• Key ERAD components SYVN1 (HRD1), UBE2J1, and UBE2G2 impact GPI-GalNAc modification

• This suggests a regulatory relationship between GPI biosynthesis and protein quality control

Glycosphingolipid Biosynthesis:

• Enzymes B3GALT4 and UGCG in glycosphingolipid synthesis affect GPI-GalNAc modification

• This indicates coordination between different glycolipid biosynthetic pathways

Transcriptomic Effects:
Gene expression analysis of TMEM246 alterations revealed impacts on multiple cellular processes:

What is the current understanding of TMEM246 structure-function relationships and how can this inform therapeutic development?

Current understanding of TMEM246 structure-function relationships is still developing:

Structural Features:

• TMEM246 is a multi-pass transmembrane protein

• Contains domains necessary for GalNAc transferase activity

• Structural details at atomic resolution are not yet available in the literature

Functional Domains:

• Catalytic domain responsible for GalNAc transfer

• Transmembrane domains that anchor the protein in the ER membrane

• Potential binding sites for GPI substrate recognition

Therapeutic Implications:

• Modulation of TMEM246 activity could potentially impact diseases where GPI-anchored proteins play key roles

• In cancer contexts where TMEM246-AS1 shows altered expression, targeting this pathway might have therapeutic value

• Understanding TMEM246's role in the ERAD pathway connections could provide new approaches for diseases involving protein quality control dysfunction

Research using knockout models and gene expression studies continues to expand our understanding of TMEM246's full biological significance and potential as a therapeutic target.